Drug Profile
BBP 398
Alternative Names: BBP-398; BMS-986466; IACS-15509; SHP2 inhibitor - Navire PharmaLatest Information Update: 10 Jan 2024
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer BridgeBio Pharma; Bristol-Myers Squibb; LianBio; Navire
- Class Antineoplastics; Indoles; Pyrazines; Small molecules
- Mechanism of Action Protein tyrosine phosphatase non receptor type 11 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Non-small cell lung cancer
Most Recent Events
- 10 Jan 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)
- 02 Nov 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT06024174)
- 13 Sep 2023 Chemical structure information added